表 3.

EORA合并CVD与不合并CVD临床特征的差异

Clinical characteristics of EORA patients with or without CVD

Items	CVD (n=59)	Without CVD (n=153)	Z/χ2	P value
Data are presented as n (%) or median (P25, P75). Abbreviations as in Table 1 and Table 2.
Male	22 (37.3)	46 (30.1)	1.02	0.313
Age/years	74 (70, 78)	70 (67, 75)	-3.12	0.002
Disease duration/years	4 (1, 8)	2 (1, 5)	-1.83	0.068
SJCs	3 (1, 8)	4 (1, 10)	-0.50	0.620
TJCs	6 (2, 15)	6 (2, 17)	-0.77	0.444
DJCs	28 (47.5)	51 (33.3)	3.63	0.057
ESR/(mm/h)	47 (30, 65)	43 (23, 71)	-0.36	0.716
CRP/(mg/L)	10.4 (2.8, 37.7)	14.0 (1.8, 46.7)	-0.77	0.442
DAS28-ESR	4.6 (3.7, 5.7)	4.5 (3.7, 5.8)	-0.47	0.636
≤2.6	6 (8.5)	10 (6.5)	0.81	0.369
>2.6, ≤3.2	4 (6.8)	11 (7.2)	0.01	>0.999
>3.2, ≤5.1	29 (49.2)	75 (49.0)	0.00	0.986
>5.1	20 (33.9)	57 (37.3)	0.21	0.649
Rheumatoid factor (positive)	14/49 (28.6)	11/121 (9.1)	10.55	0.001
Anti-CCP antibody (positive)	10/30 (33.3)	13/79 (16.5)	3.72	0.054
Extra-articular manifestations
Interstitial lung disease	16 (27.1)	34 (22.2)	0.57	0.452
Pleural effusion	2 (3.4)	1 (0.6)	2.29	0.188
Pericardial effusion	1 (1.7)	0 (0)	2.606	0.278
Rheumatoid nodules	7 (11.9)	6 (3.9)	4.67	0.050
Cutaneous vasculitis	0 (0)	1 (0.6)	0.387	>0.999
Anemia	10 (16.9)	24 (15.7)	0.050	0.822
Peri-neuropathy	0 (0)	1 (0.6)	0.387	>0.999
Sjögren's syndrome	4 (6.8)	7 (4.6)	0.421	0.503
Medications
Non-DMARDs	16 (27.1)	59 (38.6)	2.44	0.118
Methotrexate	9 (15.3)	54 (35.3)	10.09	0.004
Hydroxychloroquine	4 (6.8)	35 (22.9)	7.35	0.007
Leflunomide	25 (42.4)	61 (39.9)	0.11	0.739
Sulfasalazine	9 (15.3)	40 (26.1)	2.84	0.092
Prednisone	18 (3.1)	32 (20.9)	2.17	0.140
Celecoxib	2 (3.3)	7 (4.6)	0.15	0.701
Biological agents	3 (5.1)	17 (11.1)	1.81	0.179